Researchers at the University of Maryland, Baltimore County (UMBC) have identified the enzyme USP15 as a promising molecular target for ovarian cancer therapy. Their study shows that ovarian cancer cells rely more heavily on USP15 than normal cells. Lowering USP15 levels slows tumor growth, disrupts chromosome separation during cell division, reduces the cancer’s ability to spread, and makes cells more sensitive to standard chemotherapy drugs. The findings, published in Molecular Therapy Oncology, open the door to more selective treatments that could reduce harm to healthy cells.

More than 250 leaders and CEOs from healthcare, biotechnology, medicine, venture capital, government and technology gathered in Boston for the 2026 World Medical Innovation Forum, convened by Mass General Brigham in collaboration with Bank of America. This year's forum, which drew more than 2,300 attendees, focused on “Innovation at Scale,” highlighting emerging treatments, artificial intelligence, scientific discovery and new approaches to improving patient care.

Scientists at the UCLA Broad Stem Cell Research Center have received $4.9 million in grants from the California Institute for Regenerative Medicine, the state’s stem cell agency, to advance new stem cell-based treatments for irreversible vision loss and infertility.